Cutaneous squamous cell carcinoma(CSCC)is the second most common type of skin cancer and typically involves the head and neck.Systemic therapy is often required for patients with advanced CSCC to achieve optimal disea...Cutaneous squamous cell carcinoma(CSCC)is the second most common type of skin cancer and typically involves the head and neck.Systemic therapy is often required for patients with advanced CSCC to achieve optimal disease control.Immune checkpoint inhibitors(ICIs)are now the standard of care for these patients,with a 50%-60%response rate and sustainable remission for at least 30%of patients.Given the activity of ICIs in advanced head and neck CSCC,ICIs are being studied in early-stage disease or neoadjuvant situations.The purpose of this review is to provide an overview of the innovative perioperative strategies in resectable disease and discuss novel immunotherapeutic strategies designed to overcome treatment resistance.In conclusion,neoadjuvant ICIs have demonstrated impressive response rates with unclear survival benefit.The effectiveness of adjuvant ICIs is currently being explored.Emerging biomarkers,such as circulating tumor DNA(ctDNA),will be crucial for optimizing patient selection and improving treatment outcomes.展开更多
Systemic therapy for metastatic renal cell carcinoma(mRCC)has advanced considerably over the past decade.Studies of systemic therapies in the adjuvant,neoadjuvant,and now perioperative settings as solitary,dual,and tr...Systemic therapy for metastatic renal cell carcinoma(mRCC)has advanced considerably over the past decade.Studies of systemic therapies in the adjuvant,neoadjuvant,and now perioperative settings as solitary,dual,and triplet combinations are underway.The timing of systemic therapy relative to extirpative surgery has yielded varying results.With the rise of novel therapeutics,new methods for risk stratification and patient selection,including initial biomarker evaluation,have begun.This perspective aims to summarize investigations into perioperative mRCC therapies and discuss the foundations of these concepts based on recent adjuvant and neoadjuvant trials,and to discuss future directions in this space.展开更多
文摘Cutaneous squamous cell carcinoma(CSCC)is the second most common type of skin cancer and typically involves the head and neck.Systemic therapy is often required for patients with advanced CSCC to achieve optimal disease control.Immune checkpoint inhibitors(ICIs)are now the standard of care for these patients,with a 50%-60%response rate and sustainable remission for at least 30%of patients.Given the activity of ICIs in advanced head and neck CSCC,ICIs are being studied in early-stage disease or neoadjuvant situations.The purpose of this review is to provide an overview of the innovative perioperative strategies in resectable disease and discuss novel immunotherapeutic strategies designed to overcome treatment resistance.In conclusion,neoadjuvant ICIs have demonstrated impressive response rates with unclear survival benefit.The effectiveness of adjuvant ICIs is currently being explored.Emerging biomarkers,such as circulating tumor DNA(ctDNA),will be crucial for optimizing patient selection and improving treatment outcomes.
基金supported by a grant from the National Cancer Institute(2P30CA016058).
文摘Systemic therapy for metastatic renal cell carcinoma(mRCC)has advanced considerably over the past decade.Studies of systemic therapies in the adjuvant,neoadjuvant,and now perioperative settings as solitary,dual,and triplet combinations are underway.The timing of systemic therapy relative to extirpative surgery has yielded varying results.With the rise of novel therapeutics,new methods for risk stratification and patient selection,including initial biomarker evaluation,have begun.This perspective aims to summarize investigations into perioperative mRCC therapies and discuss the foundations of these concepts based on recent adjuvant and neoadjuvant trials,and to discuss future directions in this space.
